JAMES MARCZAK: Open Payments
NPI 1720123805 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,614 in 77 payments from 16 companies in 2025. Trend: 2023 $1,202 · 2024 $1,343 · 2025 $2,614
Food & beverage: $2,614
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $1,254 |
| ABBVIE INC. | 15 | $328 |
| Novo Nordisk Inc | 13 | $287 |
| Amgen Inc. | 16 | $242 |
| PFIZER INC. | 6 | $196 |
| Axsome Therapeutics, Inc. | 2 | $63 |
| Eisai Inc. | 2 | $62 |
| Abbott Laboratories | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Medtronic, Inc. | 1 | $24 |
Products named: BREZTRI, AIRSUPRA, VRAYLAR, Ozempic, REPATHA, TEZSPIRE, NURTEC ODT, OTEZLA.
Industry payments across AZ — which companies pay providers there.
